Cardiovascular health, heart failure, atherosclerosis, and cardiac research
419 artigos
The DECISION trial finds low-dose digoxin did not significantly cut hospitalizations or cardiovascular death in 1,001 HFrEF/HFmrEF patients.
A phase 2 trial of the microRNA-132 inhibitor CDR132L showed safety but no significant improvement in cardiac remodeling after heart attack.
A 2025 review maps the molecular drivers of cardiac aging and evaluates drugs, CRISPR, stem cells, and lifestyle as countermeasures.
The PRAISE-MR trial finds sacubitril/valsartan significantly improves exercise hemodynamics and quality of life in a high-risk HFpEF phenotype.
A JAMA meta-analysis of 9,000+ patients finds digitalis glycosides significantly reduce worsening heart failure events, reigniting interest in a centuries-old drug.
A comprehensive review reveals how inflammaging—the fusion of aging and inflammation—fuels cardiovascular disease through senescence, mitochondrial dysfunction, and gut dysbiosis.
New JAMA research links syphilis infection to a meaningfully higher risk of certain cardiovascular outcomes, raising screening urgency.
A completed trial tested whether seismocardiography can accurately estimate VO2max and biological age without exhaustive exercise testing.
Scientists identify GPRASP1 as a key guardian of pulmonary vascular health, opening a potential drug target for PH-HFpEF.
A specific CD40 signaling branch boosts macrophage cleanup of dead cells after MI, improving cardiac recovery in mice.
A new review examines how drugs that clear senescent cells could transform treatment of age-related cardiovascular disease.
A new review reveals how sirtuin enzymes regulate cardiac fibrosis and why targeting them could reshape heart failure treatment.
